Feedback    Advertise    Submit Papers    Reprints    About    Help    Contact   
Upstream Processing Downstream Processing Manufacturing Analytical Facilities
Archive by Issue Archive by Article Type Supplements
CMC Forum Press Releases
In-Process Control of pDNA Production on CIMac pDNA Analytical Column
Boštjan Gabor, Urh Černigoj, Franci Smrekar
BioProcess International, Vol. 8, No. 7, July–August 2010, pp. 32–33
 



As the demand for plasmid DNA (pDNA)–based gene therapy and vaccines increases, large-scale, cost-effective, and reproducible pDNA production will be required. The key to success is a real-time, in-process control method that ensures a high percentage of supercoiled pDNA in the final product. CIMac pDNA Analytical Column allows the monitoring of degradation products (open circular and linear pDNA), the removal of impurities (RNA), and the assurance that each production step is yielding the amount of supercoiled pDNA anticipated.



An example of a pDNA purification processs (Figure 1) based on our CIM HIP2 Plasmid Process Pack (for details please check the product brochure or visit our website) with in-process control steps is shown in Figure 3. The final product composition is confirmed by agarose gel electrophoresis (Figure 2). In Figure 4, the complete separation of all three pDNA conformations from a test solution within 10 minutes on the CIMac pDNA Analytical Column (Figure 2) shows the versatility of the column (photo).



Results

When used as part of a complete production process, each in-process control check is completed in less than 18 minutes (Figure 3), enabling the comparison of real-time data during the production of your gene therapy or vaccine product; saving time and expensive wastage. In addition, CIMac pDNA Analytical Column enables the separation of all three pDNA conformations (Figure 4) and is able to monitor the removal of other impurities such as RNA.





CIMac pDNA Analytical Column allows quality control to ensure that each batch has the highest level of supercoiled pDNA and the minimum amount of impurities in real time to ensure an efficient and cost-effective gene therapy/vaccine production run.



Author Details
Boštjan Gabor; Urh Cernigoj, PhD; and Franci Smrekar are researchers in the applications laboratory at BIA Separations, Teslova 30, SI-1000 Ljubljana, Slovenia, 386-1-426-5649; bostjan.gabor@monoliths.com; urh.cernigoj@monoliths.com; franci.smrekar@monoliths.com; www.biaseparations.com.

 
| | Share
Biopharmaceutical Production
Facility Design Strategies for Single-Use Technologies

Please join us for a free webinar addressing strategies for facility design in biopharmaceutical manufacturing:

Wednesday, 29 February 2012
8:00 AM and 1:00 PM EST

Presented by:

Ingrid Long, MSc
Research Engineer
GE Healthcare Life Sciences

Register today!

During the webinar, Ms. Long will discuss the impact of different strategies for facility design, with a focus on the following topics:

* Replacement of traditional equipment with the single-use equivalent
* Biopharmaceutical manufacturing in a single room
* Benefits of facility design with respect to cost, risk, and flexibility

Register today!


Nine Conferences — One Location: Hilton Bayfront (San Diego, CA)
Webinars   
Subscribe   
Reprints   
Contact   
About   
Informa plc
©2002 - 2009 BioProcess International
Ph: 508-616-5550